Dr. Hatou presented recent research progress in 2019 ISSCR annual conference.

Los Angeles (JUNE 29, 2019)-, Dr. Hatou, founder & CEO of Cellusion Inc., presented recent research progress in 2019 International Society for Stem Cell Research (ISSCR) annual conference held in Los Angeles from June 26th to 29th. The title of the presentation is that Direct Production of Corneal Endothelial -Cells from Human iPS Cells by Omitting Neural Crest Differentiation-. With our cutting-edge cellular technology, Cellusion will promote our research program to deliver novel therapies for all bullous keratopathy patients.

Details on ISSCR, please see below.
http://www.isscr.org/
For further information: please ask us through contact form in our website.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：2-4-15 Minamiaoyama, Minato, Tokyo 107-0062, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/